To determine if FGF2 can augment the anti-fibrotic properties of SMSCs in CES in suppressing the fibrotic phenotype in myofibroblasts, especially in the presence of TGF-β1, we evaluated its activity in the in vitro fibrosis model described above. The gene discussed is FGF2; the disease is fibrosis.